Boston Scientific (BSX) slides as 2026 outlook and legal/regulatory overhang weigh on sentiment

Boston Scientific Corporation (BSX) is down 8.2% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is investor de-risking after the company’s latest outlook pointed to a slowdown from an unusually strong prior-year growth rate, with additional pressure from concerns around specific business lines and ongoing legal/regulatory headlines. If there was no single company-specific news item today, the move could reflect a continuation of the post-guidance repricing and heightened sensitivity to negative updates.

Details:

The company’s forward guidance for 2026 implied more modest growth versus the prior year and was viewed as slightly below consensus on key profit metrics, which can trigger a reset in valuation expectations.

Management commentary has highlighted mix and operational items that may temporarily weigh on reported growth (including impacts tied to portfolio changes and product actions), which can amplify near-term uncertainty.

Investor litigation has been filed around prior disclosures and business expectations; even without new court developments, class-action headlines can add an overhang and raise perceived risk.

Some analysts have recently pointed to procedure-area concerns (including in atrial fibrillation) when adjusting price targets, which can contribute to multiple compression during risk-off sessions.

Sources:

Yahoo Finance, Boston Scientific Investor Relations, TipRanks, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$BSX Insider Trading Activity

$BSX insiders have traded $BSX stock on the open market 11 times in the past 6 months. Of those trades, 0 have been purchases and 11 have been sales.

Here’s a breakdown of recent trading of $BSX stock by insiders over the last 6 months:

MICHAEL F MAHONEY (Chairman, President & CEO) has made 0 purchases and 2 sales selling 160,901 shares for an estimated $15,043,394.
JOSEPH MICHAEL FITZGERALD (EVP & Group Pres, Cardiology) has made 0 purchases and 5 sales selling 100,000 shares for an estimated $9,896,664.
ELLEN M ZANE has made 0 purchases and 3 sales selling 25,782 shares for an estimated $2,573,877.
ARTHUR C BUTCHER (EVP& Grp Pres, MedSurg & APAC) sold 17,313 shares for an estimated $1,758,188

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$BSX Hedge Fund Activity

We have seen 816 institutional investors add shares of $BSX stock to their portfolio, and 939 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 32,976,583 shares (-75.1%) from their portfolio in Q4 2025, for an estimated $3,144,317,189
BLACKROCK, INC. removed 9,188,624 shares (-6.3%) from their portfolio in Q4 2025, for an estimated $876,135,298
BANK OF AMERICA CORP /DE/ removed 8,753,856 shares (-25.8%) from their portfolio in Q4 2025, for an estimated $834,680,169
MARSHALL WACE, LLP removed 6,841,803 shares (-69.8%) from their portfolio in Q4 2025, for an estimated $652,365,916
WELLINGTON MANAGEMENT GROUP LLP removed 4,944,352 shares (-33.7%) from their portfolio in Q4 2025, for an estimated $471,443,963
DZ BANK AG DEUTSCHE ZENTRAL GENOSSENSCHAFTS BANK, FRANKFURT AM MAIN added 4,508,152 shares (+32.1%) to their portfolio in Q4 2025, for an estimated $429,852,293
UBS GROUP AG added 4,304,984 shares (+40.7%) to their portfolio in Q4 2025, for an estimated $410,480,224

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$BSX Government Contracts

We have seen $22,801,533 of award payments to $BSX over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

THERASPHERE Y-90 GLASS MICROSPHERE MEDICATION: $1,260,000
Y90 THERASPHERE: $1,155,000
VAPAHCS THERASPHERE Y90 RADIOPHARMACEUTICALS: $954,240
THERASPHERE YTTIRUM-90 (Y-90) GLASS: $833,910
THERASPHERE Y-90: $693,000

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.

$BSX Congressional Stock Trading

Members of Congress have traded $BSX stock 11 times in the past 6 months. Of those trades, 6 have been purchases and 5 have been sales.

Here’s a breakdown of recent trading of $BSX stock by members of Congress over the last 6 months:

REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 5 times. They made 4 purchases worth up to $60,000 on 02/10, 01/30, 11/18, 10/17 and 1 sale worth up to $15,000 on 12/24.
SENATOR MARKWAYNE MULLIN purchased up to $50,000 on 12/29.
SENATOR JOHN BOOZMAN sold up to $15,000 on 12/17.
REPRESENTATIVE LISA C. MCCLAIN has traded it 3 times. They made 1 purchase worth up to $15,000 on 10/30 and 2 sales worth up to $30,000 on 10/31, 10/30.
REPRESENTATIVE KEVIN HERN sold up to $50,000 on 10/28.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

$BSX Analyst Ratings

Wall Street analysts have issued reports on $BSX in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Needham issued a "Buy" rating on 02/05/2026
Truist Securities issued a "Buy" rating on 02/05/2026
BTIG issued a "Buy" rating on 02/04/2026
RBC Capital issued a "Outperform" rating on 12/17/2025
UBS issued a "Buy" rating on 10/23/2025
Evercore ISI Group issued a "Outperform" rating on 10/07/2025

To track analyst ratings and price targets for $BSX, check out Quiver Quantitative's $BSX forecast page.

$BSX Price Targets

Multiple analysts have issued price targets for $BSX recently. We have seen 19 analysts offer price targets for $BSX in the last 6 months, with a median target of $100.0.

Here are some recent targets:

Jayson Bedford from Raymond James set a target price of $88.0 on 03/30/2026
Mike Matson from Needham set a target price of $97.0 on 03/30/2026
David Roman from Goldman Sachs set a target price of $93.0 on 03/27/2026
Rick Wise from Stifel set a target price of $90.0 on 03/20/2026
Richard Newitter from Truist Securities set a target price of $92.0 on 03/18/2026
Danielle Antalffy from UBS set a target price of $105.0 on 03/17/2026
Joanne Wuensch from Citigroup set a target price of $94.0 on 03/11/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.